Cabaletta Bio Inc (NASDAQ: CABA) presented updated data from the DesCAARTes trial, evaluating DSG3-CAART in adults with mucosal-dominant pemphigus vulgaris (mPV), a blistering skin disease that ...
PHILADELPHIA--(BUSINESS WIRE)-- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B ...
PHILADELPHIA, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for ...
PHILADELPHIA, May 02, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for ...
DSG3-CAART achieved autoantibody elimination and resolution of blisters in active immune mouse model of pemphigus vulgaris Soluble autoantibodies demonstrated potential to enhance DSG3-CAART efficacy ...
* CABALETTA BIO INC - FDA HAS GRANTED FAST TRACK DESIGNATION FOR DSG3-CAART (DESMOGLEIN 3 CHIMERIC AUTOANTIBODY RECEPTOR T CELLS) * CABALETTA BIO - PLANS TO INITIATE PHASE 1 DESCAARTES TRIAL TO ...
PHILADELPHIA--(BUSINESS WIRE)--Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results